Clinical Trials for Cervical Cancer

Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Platinum Refractory Disease

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with platinum-refractory recurrent/metastatic HNSCC (oral cavity, oropharynx, larynx, hypopharynx), PD-L1 CPS ≥1, ECOG 0–2, and no prior systemic therapy for R/M disease are randomized to pembrolizumab alone vs pembrolizumab plus cetuximab. Pembrolizumab is an anti–PD-1 antibody; cetuximab is an anti-EGFR antibody, with the combination tested to enhance efficacy in this setting.

ClinicalTrials.gov ID: NCT06589804

A Phase II Trial of Lovastatin and Pembrolizumab in Patients with RM HNSCC (LAPP)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma (ECOG 0–1) not candidates for salvage surgery receive pembrolizumab plus oral lovastatin; prior checkpoint inhibitor use and current statin therapy are excluded. Pembrolizumab is an anti–PD-1 antibody, and lovastatin (HMG‑CoA reductase inhibitor) is added to potentially enhance antitumor immunity via mevalonate pathway inhibition.

ClinicalTrials.gov ID: NCT06636734

Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent/metastatic nasopharyngeal carcinoma after platinum–gemcitabine and prior PD‑1/L1 therapy (up to two prior lines; ECOG 0–2; treated/stable brain mets allowed) are randomized to nivolumab (PD‑1) plus ipilimumab (CTLA‑4) with or without cabozantinib, a multikinase inhibitor of MET/VEGFR2/AXL. Aims to determine whether adding cabozantinib improves outcomes versus dual checkpoint blockade alone.

ClinicalTrials.gov ID: NCT05904080

Single-Arm Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naïve Participants

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent or metastatic nasopharyngeal carcinoma, systemic treatment–naïve for the metastatic setting and with measurable disease, receive induction gemcitabine/platinum plus toripalimab (anti–PD-1), with optional switch to carboplatin from cycle 2, followed by maintenance toripalimab. Excludes candidates for curative local therapy, prior systemic therapy for R/M disease, early recurrence after chemoradiation (<6 months), rapidly progressive disease, and active/untreated CNS metastases.

ClinicalTrials.gov ID: NCT06457503

A Randomized Phase III TriaL Comparing SingLe- Versus Multi-Fraction Spine STereotActic Radiosurgery for Patients With Spinal Metastases (ALL-STAR)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic disease to 1–3 spinal sites (cervical/thoracic/lumbar; ECOG 0–2; no overlapping radiation, prior surgery at the site, myeloma/lymphoma, major neurologic deficits, or high SINS) are randomized to spine SRS delivered as 22 Gy × 1 versus 14 Gy × 2. The trial compares 1-year local control, safety, pain, vertebral fracture risk, and patient-reported outcomes between these standard SBRT regimens.

ClinicalTrials.gov ID: NCT06173401

Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK Fusions

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling children and adults with NTRK1/2/3 fusion–positive differentiated thyroid cancer (post-thyroidectomy) with CT-evaluable pulmonary metastases and no prior RAI or systemic therapy. Patients receive a 6-month lead-in of larotrectinib (selective TRKA/B/C inhibitor) followed by radioactive iodine (131I), aiming to enhance RAI avidity and induce complete pulmonary responses.

ClinicalTrials.gov ID: NCT05783323

A Phase II Trial of Belzutifan in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study of oral belzutifan, a selective HIF-2α inhibitor, for adults with recurrent or persistent clear cell ovarian carcinoma (≥50% clear cell if mixed) with measurable disease after at least one prior platinum regimen; prior bevacizumab and immunotherapy allowed and treated/stable brain metastases permitted. Patients receive daily belzutifan in 28-day cycles until progression/toxicity, with primary endpoints of ORR and 6-month PFS; class-toxicities include anemia and hypoxia.

ClinicalTrials.gov ID: NCT06677190

A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors including HNSCC, pancreatic adenocarcinoma, NSCLC, HR+/HER2− breast cancer post‑CDK4/6 inhibitor, or platinum‑resistant high‑grade serous ovarian/related cancers receive the oral CDK7 inhibitor GTAEXS617 (transcription/cell‑cycle regulator) as monotherapy or combined with standard-of-care regimens. Eligible patients have ECOG 0–1 and adequate organ function; study explores safety, PK, and preliminary activity with tumor biopsies required.

ClinicalTrials.gov ID: NCT05985655

Randomized Phase II Trial of Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with symptomatic or progressive radioactive iodine–resistant differentiated thyroid cancer (papillary/follicular/Hürthle; ECOG 0–2; ≤1 prior VEGF/VEGFR therapy) are randomized to lenvatinib monotherapy starting at 24 mg/day versus 10 mg/day. Lenvatinib is a multikinase inhibitor of VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT; the study tests whether a lower starting dose improves tolerability without compromising antitumor activity.

ClinicalTrials.gov ID: NCT07092514

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors eligible for on-label PD-1 therapy (nivolumab or pembrolizumab) are randomized in a crossover design to receive standard PD-1 inhibitors via subcutaneous versus intravenous administration, assessing patient/clinician preference, satisfaction, QoL, safety, and selected clinical outcomes. Includes PD-(L)1–naïve patients or those willing to switch; excludes prior severe hypersensitivity and transplant history.

ClinicalTrials.gov ID: NCT07223424